Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Net revenues	$ 58,054	$ 56,197	$ 45,804
Cost of products sold	17,414	17,446	15,387
Selling, general and administrative	15,260	12,349	11,299
Research and development	6,510	6,922	6,379
Acquired IPR&D and milestones	697	1,124	1,376
Other operating expense, net	56	432	0
Total operating costs and expenses	39,937	38,273	34,441
Operating earnings	18,117	17,924	11,363
Interest expense, net	2,044	2,384	2,280
Net foreign exchange loss	148	51	71
Other expense, net	2,448	2,500	5,614
Earnings before income tax expense	13,477	12,989	3,398
Income tax expense (benefit)	1,632	1,440	(1,224)
Net earnings	11,845	11,549	4,622
Net earnings attributable to noncontrolling interest	9	7	6
Net earnings attributable to AbbVie Inc.	$ 11,836	$ 11,542	$ 4,616
Per share data
Basic earnings per share (in dollars per share)	$ 6.65	$ 6.48	$ 2.73
Diluted earnings per share (in dollars per share)	$ 6.63	$ 6.45	$ 2.72
Weighted-average basic shares outstanding (in shares)	1,771	1,770	1,667
Weighted-average diluted shares outstanding (in shares)	1,778	1,777	1,673